Abecma FDA Approval History
Last updated by Judith Stewart, BPharm on June 30, 2025.
FDA Approved: Yes (First approved March 26, 2021)
Brand name: Abecma
Generic name: idecabtagene vicleucel
Dosage form: Suspension for Intravenous Infusion
Company: Bristol-Myers Squibb Company
Treatment for: Multiple Myeloma
Abecma (idecabtagene vicleucel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
- Abecma is a customized treatment created by using a patient’s own T-cells, which are collected and genetically modified to recognize and attack multiple myeloma cells. Once modified, the cells are infused back into the patient.
- Abecma is administered as an intravenous infusion two days after pretreatment with a 3-day lymphodepleting chemotherapy regimen.
- Abecma (idecabtagene vicleucel) treatment may cause serious adverse reactions. The Abecma product label carries a boxed warning for cytokine release syndrome (CRS), hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), neurologic toxicity, and prolonged cytopenia, and T cell malignancies - all of which can be fatal or life-threatening.
- Common adverse reactions include pyrexia, CRS, hypogammaglobulinemia, infections, musculoskeletal pain, fatigue, febrile neutropenia, hypotension, tachycardia, diarrhea, nausea, headache, chills, upper respiratory tract infection, encephalopathy, edema, dyspnea and viral infections.
Common laboratory adverse reactions include decreased leukocyte count, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, and decreased hemoglobin.
Development timeline for Abecma
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.